

# Bibliografía

- 1 Granado de la Orden S, Saá Requejo C, Quintás Viqueira A. Situación epidemiológica del cáncer de próstata en España. *Actas Urol Esp.* 2006;30(6):574-82.
- 2 Ministerio de Sanidad y Consumo. La situación del Cáncer en España. 2005.
- 3 Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. *Eur J Cancer.* 2001;37 Suppl 8:S4-66.
- 4 European Association of Urology, Aus G, Abbou CC, Bolla M, Heidenreich A, Van Poppel H., et al. EAU Guidelines on Prostate Cancer. 2007.
- 5 Verdecchia A, Micheli A, Colonna M, Moreno V, Izarzugaza MI, Paci E. A comparative analysis of cancer prevalence in cancer registry areas of France, Italy and Spain. *Ann Oncol.* 2002;13(7):1128-39.
- 6 Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. *Eur J Cancer.* 1997;33(7):1075-107.
- 7 Centro Nacional de Epidemiología (CNE). Instituto de Salud Carlos III. Servidor Interactivo de Información Epidemiológica. Ariadna: Mortalidad por cáncer y otras causas. Gráficas. Última actualización: 6 de febrero de 2008 [consultada 10 marzo de 2008]. Disponible en: <http://cne.isciii.es>.
- 8 Chong CC, Austen L, Kneebone A, Lalak A, Jalaludin B. Patterns of practice in the management of prostate cancer: results from multidisciplinary surveys of clinicians in Australia and New Zealand in 1995 and 2000. *BJU Int.* 2006;97(5):975-80.
- 9 Fleshner N, Rakovitch E, Klotz L. Differences between urologists in the United States and Canada in the approach to prostate cancer. *J Urol.* 2000;163(5):1461-6.
- 10 Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. *J Clin Oncol.* 1995;13(1):93-100.
- 11 Cazzaniga LF, Marinoni MA, Bossi A, Bianchi E, Cagna E, Cosentino D, et al. Interphysician variability in defining the planning target volume in the irradiation of prostate and seminal vesicles. *Radiother Oncol.* 1998;47(3):293-6.
- 12 Ellison LM, Trock BJ, Poe NR, Partin AW. The effect of hospital volume on cancer control after radical prostatectomy. *J Urol.* 2005;173(6):2094-8.
- 13 The Center for the Evaluative Clinical Sciences. Dartmouth Medical School. The Quality of Medical Care in the United States: A report on the Medicare Program. The Dartmouth Atlas of Health Care. 1999.
- 14 Grupo de trabajo sobre GPC. Elaboración de Guías de Práctica Clínica en el Sistema Nacional de Salud. Manual Metodológico. Madrid: Plan Nacional para el SNS del MSC. Instituto Aragonés de Ciencias de la Salud-I+CS; 2007. Guías de Práctica Clínica en el SNS: I+CS N° 2006/OI.
- 15 National Comprehensive Cancer Network (NCCN). Prostate Cancer. Practice Guidelines in Oncology. 2008. Report No: v.1.2008.
- 16 National Institute for Health and Clinical Excellence (NICE). Clinical Guideline. Prostate Cancer: diagnosis and treatment. Full Guideline. 2008 Feb.
- 17 National Institute for Health and Clinical Excellence (NICE). Clinical Guideline. Prostate Cancer: diagnosis and treatment. Evidence review. 2008 Feb.
- 18 AATRM (Agència d'Avaluació de Tecnologia i Recerca Mèdiques), CatSalut, Departament de Sanitat i Seguretat Social (Generalitat de Catalunya). OncoGuía de Próstata. 2004 Nov. Report No.: OG02/2004.

- 19 Ministerio de Sanidad y Consumo. Estrategia en cáncer del Sistema Nacional de Salud. 2006.
- 20 The AGREE Collaboration. AGREE Instrument Spanish version. Última actualización: septiembre de 2001 [consultada 10 marzo de 2008]. Disponible en: <http://www.agreecollaboration.org>.
- 21 Etxeberria A, Rotaeche R, Lekue I, Callén B, Merino M, Villar M, et al. Descripción de la metodología de elaboración- adaptación- actualización empleada en la guía de práctica clínica sobre asma de la CAPV. Proyecto de Investigación Comisionada. Vitoria-Gasteiz. Departamento de Sanidad. Gobierno Vasco, 2005. Informe n°: Osteba D-05-03.
- 22 Scottish Intercollegiate Guidelines Network (SIGN). Edinburgh. A guideline developers' handbook (Publication n° 50). Revised edition. Última actualización: enero de 2008 [consultada 10 marzo de 2008]. Disponible en: <http://www.sign.ac.uk/guidelines/fulltext/50/index.html>.
- 23 Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. *J Urol*. 1974;111(1):58-64.
- 24 Epstein JI, Allsbrook WC, Jr., Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. *Am J Surg Pathol*. 2005;29(9):1228-42.
- 25 Wallen MJ, Linja M, Kaartinen K, Schleutker J, Visakorpi T. Androgen receptor gene mutations in hormone-refractory prostate cancer. *J Pathol*. 1999;189(4):559-63.
- 26 Segawa N, Mori I, Utsunomiya H, Nakamura M, Nakamura Y, Shan L, et al. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. *Pathol Int*. 2001;51(6):452-9.
- 27 Miyoshi Y, Ishiguro H, Uemura H, Fujinami K, Miyamoto H, Miyoshi Y, et al. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. *Prostate*. 2003;56(4):280-6.
- 28 Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. *Cancer Res*. 1994;54(20):5474-8.
- 29 Sadi MV, Barrack ER. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. *Cancer*. 1993;71(8):2574-80.
- 30 Magi-Galluzzi C, Xu X, Hlatky L, Hahnfeldt P, Kaplan I, Hsiao P, et al. Heterogeneity of androgen receptor content in advanced prostate cancer. *Mod Pathol*. 1997;10(8):839-45.
- 31 D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. *JAMA*. 1998;280(11):969-74.
- 32 D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. *J Clin Oncol*. 2002;20(23):4567-73.
- 33 Buhmeida A, Pyrhonen S, Laato M, Collan Y. Prognostic factors in prostate cancer. *Diagn Pathol*. 2006;1:4.
- 34 McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Capsular penetration in prostate cancer. Significance for natural history and treatment. *Am J Surg Pathol*. 1990;14(3):240-7.
- 35 Epstein JI, Carmichael M, Partin AW, Walsh PC. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. *J Urol*. 1993;149(6):1478-81.
- 36 Salomon L, Levrel O, Anastasiadis AG, Irani J, De La TA, Saint F, et al. Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. *Eur Urol*. 2003;43(1):39-44.

- 37 Bostwick DG. Grading prostate cancer. *Am J Clin Pathol*. 1994;102(4 Suppl 1):S38-S56.
- 38 Sogani PC, Israel A, Lieberman PH, Lesser ML, Whitmore WF, Jr. Gleason grading of prostate cancer: a predictor of survival. *Urology*. 1985;25(3):223-7.
- 39 Rioux-Leclercq NC, Chan DY, Epstein JI. Prediction of outcome after radical prostatectomy in men with organ-confined Gleason score 8 to 10 adenocarcinoma. *Urology*. 2002;60(4):666-9.
- 40 Epstein JI, Carmichael M, Walsh PC. Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade and margins of resection to prognosis. *J Urol*. 1993;149(5):1040-5.
- 41 Björk T, Lilja H, Christensson A. The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer. *BJU Int*. 1999;84(9):1021-7.
- 42 D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. *N Engl J Med*. 2004;351(2):125-35.
- 43 Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. *BJU Int*. 2005;95(6):751-6.
- 44 Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. *JAMA*. 1999;281(17):1591-7.
- 45 D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. *JAMA*. 2005;294(4):440-7.
- 46 Barry MJ, Albertsen PC, Bagshaw MA, Blute ML, Cox R, Middleton RG, et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management: a retrospective analysis. *Cancer*. 2001;91(12):2302-14.
- 47 Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. *JAMA*. 2005;293(17):2095-101.
- 48 Cheng L, Koch MO, Juliar BE, Daggy JK, Foster RS, Bihrl R, et al. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. *J Clin Oncol*. 2005;23(13):2911-7.
- 49 Djavan B, Kadesky K, Klopukh B, Marberger M, Roehrborn CG. Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens. *Eur Urol*. 1998;33(3):261-70.
- 50 Ross JS, Figge H, Bui HX, del Rosario AD, Jennings TA, Rifkin MD, et al. Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer. *Cancer*. 1994;74(10):2811-8.
- 51 Koksall IT, Ozcan F, Kadioglu TC, Esen T, Kilicaslan I, Tunc M. Discrepancy between Gleason scores of biopsy and radical prostatectomy specimens. *Eur Urol*. 2000;37(6):670-4.
- 52 Shen BY, Tsui KH, Chang PL, Chuang CK, Hsieh ML, Huang ST, et al. Correlation between the Gleason scores of needle biopsies and radical prostatectomy specimens. *Chang Gung Med J*. 2003;26(12):919-24.
- 53 Bloom KD, Richie JP, Schultz D, Renshaw A, Saegaert T, D'Amico AV. Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors. *Urology*. 2004;63(2):333-6.
- 54 Zagars GK. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. *Int J Radiat Oncol Biol Phys*. 1992;23(1):47-53.
- 55 Kuriyama M, Obata K, Miyagawa Y, Nishikawa E, Koide T, Takeda A, et al. Serum prostate-specific antigen values for the prediction of clinical stage and prognosis in patients with prostate cancer: an analysis of 749 cases. *Int J Urol*. 1996;3(6):462-7.

- 56 McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. *Am J Surg Pathol*. 1988;12(12):897-906.
- 57 Greene DR, Wheeler TM, Egawa S, Dunn JK, Scardino PT. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. *J Urol*. 1991;146(4):1069-76.
- 58 Augustin H, Hammerer PG, Blonski J, Graefen M, Palisaar J, Daghofer F, et al. Zonal location of prostate cancer: significance for disease-free survival after radical prostatectomy? *Urology*. 2003;62(1):79-85.
- 59 Jack GS, Cookson MS, Coffey CS, Vader V, Roberts RL, Chang SS, et al. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors. *J Urol*. 2002;168(2):519-24.
- 60 Djavan B, Susani M, Bursa B, Basharkhah A, Simak R, Marberger M. Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. *Tech Urol*. 1999;5(3):139-42.
- 61 Wheeler TM, Dilliogluligil O, Kattan MW, Arakawa A, Soh S, Suyama K, et al. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. *Hum Pathol*. 1998;29(8):856-62.
- 62 Halvorsen OJ, Haukaas S, Hoisaeter PA, Akslen LA. Independent prognostic importance of microvessel density in clinically localized prostate cancer. *Anticancer Res*. 2000;20(5C):3791-9.
- 63 Theiss M, Wirth MP, Manseck A, Frohmuller HG. Prognostic significance of capsular invasion and capsular penetration in patients with clinically localized prostate cancer undergoing radical prostatectomy. *Prostate*. 1995;27(1):13-7.
- 64 Freedland SJ, Aronson WJ, Presti JC, Jr., Amling CL, Terris MK, Trock B, et al. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. *Cancer*. 2004;100(8):1633-8.
- 65 Bostwick DG, Graham SD, Jr., Napalkov P, Abrahamsson PA, di Sant'agnese PA, Algaba F, et al. Staging of early prostate cancer: a proposed tumor volume-based prognostic index. *Urology*. 1993;41(5):403-11.
- 66 Debras B, Guillonneau B, Bougaran J, Chambon E, Vallancien G. Prognostic significance of seminal vesicle invasion on the radical prostatectomy specimen. Rationale for seminal vesicle biopsies. *Eur Urol*. 1998;33(3):271-7.
- 67 Kikuchi E, Scardino PT, Wheeler TM, Slawin KM, Ohori M. Is tumor volume an independent prognostic factor in clinically localized prostate cancer? *J Urol*. 2004;172(2):508-11.
- 68 Herold DM, Hanlon AL, Movsas B, Hanks GE. Age-related prostate cancer metastases. *Urology*. 1998;51(6):985-90.
- 69 Obek C, Lai S, Sadek S, Civantos F, Soloway MS. Age as a prognostic factor for disease recurrence after radical prostatectomy. *Urology*. 1999;54(3):533-8.
- 70 Freedland SJ, Presti JC, Jr., Kane CJ, Aronson WJ, Terris MK, Dorey F, et al. Do younger men have better biochemical outcomes after radical prostatectomy? *Urology*. 2004;63(3):518-22.
- 71 Gronberg H, Damber JE, Jonsson H, Lenner P. Patient age as a prognostic factor in prostate cancer. *J Urol*. 1994;152(3):892-5.
- 72 Austin JP, Convery K. Age-race interaction in prostatic adenocarcinoma treated with external beam irradiation. *Am J Clin Oncol*. 1993;16(2):140-5.
- 73 Hall MC, Troncoso P, Pollack A, Zhau HY, Zagars GK, Chung LW, et al. Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. *Urology*. 1994;44(6):869-75.

- 74 Borre M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. *Br J Cancer*. 1998;78(7):940-4.
- 75 Strohmeyer D, Rossing C, Strauss F, Bauerfeind A, Kaufmann O, Loening S. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. *Prostate*. 2000;42(1):26-33.
- 76 Rubin MA, Buyyounouski M, Bagiella E, Sharir S, Neugut A, Benson M, et al. Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. *Urology*. 1999;53(3):542-7.
- 77 Eichenberger T, Mihatsch MJ, Oberholzer M, Gschwind R, Rutishauser G. Are nuclear shape factors good predictors of the disease course in patients with carcinoma of the prostate. *Prog Clin Biol Res*. 1987;243A:533-7.
- 78 Partin AW, Walsh AC, Pitcock RV, Mohler JL, Epstein JI, Coffey DS. A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. *J Urol*. 1989;142(5):1254-8.
- 79 Aragona F, Franco V, Rodolico V, Dardanoni G, Cabibi D, Melloni D, et al. Interactive computerized morphometric analysis for the differential diagnosis between dysplasia and well differentiated adenocarcinoma of the prostate. *Urol Res*. 1989;17(1):35-40.
- 80 Vesalainen S, Lipponen P, Talja M, Kasurinen J, Syrjanen K. Nuclear morphometry is of independent prognostic value only in T1 prostatic adenocarcinomas. *Prostate*. 1995;27(2):110-7.
- 81 Buhmeida A, Kuopio T, Collan Y. Nuclear size and shape in fine needle aspiration biopsy samples of the prostate. *Anal Quant Cytol Histol*. 2000;22(4):291-8.
- 82 Martínez-Jabaloyas JM, Ruiz-Cerdá JL, Hernández M, Jiménez A, Jiménez-Cruz F. Prognostic value of DNA ploidy and nuclear morphometry in prostate cancer treated with androgen deprivation. *Urology*. 2002;59(5):715-20.
- 83 Martínez Jabaloyas JM, Jiménez Sánchez A, Ruiz Cerdá JL, Sanz Chinesta S, Sempere A, Jiménez Cruz JF. Valor pronóstico de la ploidía del ADN y la morfometría nuclear en el cáncer de próstata metastásico. *Actas Urol Esp*. 2004;28(4):298-307.
- 84 Maffini MV, Ortega HH, Stoker C, Giardina RH, Luque EH, Munoz de Toro MM. Bcl-2 correlates with tumor ploidy and nuclear morphology in early stage prostate carcinoma. A fine needle aspiration biopsy study. *Pathol Res Pract*. 2001;197(7):487-92.
- 85 Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. *Cancer Res*. 1994;54(14):3929-33.
- 86 Umbas R, Isaacs WB, Bringuier PP, Xue Y, Debruyne FM, Schalken JA. Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. *Int J Cancer*. 1997;74(4):374-7.
- 87 Aaltomaa S, Lipponen P, la-Opas M, Eskelinen M, Kosma VM. Alpha-catenin expression has prognostic value in local and locally advanced prostate cancer. *Br J Cancer*. 1999;80(3-4):477-82.
- 88 De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. *Urology*. 1999;53(4):707-13.
- 89 Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. *J Natl Cancer Inst*. 2003;95(9):661-8.
- 90 Mita K, Nakahara M, Usui T. Expression of the insulin-like growth factor system and cancer progression in hormone-treated prostate cancer patients. *Int J Urol*. 2000;7(9):321-9.
- 91 Figueroa JA, De RS, Tadlock L, Speights VO, Rinehart JJ. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. *J Urol*. 1998;159(4):1379-83.

- 92 Yu H, Nicar MR, Shi R, Berkel HJ, Nam R, Trachtenberg J, et al. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. *Urology*. 2001;57(3):471-5.
- 93 Thomas DJ, Robinson M, King P, Hasan T, Charlton R, Martin J, et al. p53 expression and clinical outcome in prostate cancer. *Br J Urol*. 1993;72(5 Pt 2):778-81.
- 94 Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. *Hum Pathol*. 1995;26(1):106-9.
- 95 Moul JW, Bettencourt MC, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, et al. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. *Surgery*. 1996;120(2):159-66.
- 96 Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. *J Urol*. 1996;156(4):1511-6.
- 97 Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. *J Natl Cancer Inst*. 1997;89(2):158-65.
- 98 Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF, Jr. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. *J Urol*. 1997;158(1):131-7.
- 99 Kuczyk MA, Serth J, Bokemeyer C, Machtens S, Minssen A, Bathke W, et al. The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy. *Eur J Cancer*. 1998;34(5):679-86.
- 100 Scherr DS, Vaughan ED, Jr., Wei J, Chung M, Felsen D, Allbright R, et al. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. *J Urol*. 1999;162(1):12-6.
- 101 Stricker HJ, Jay JK, Linden MD, Tamboli P, Amin MB. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. *Urology*. 1996;47(3):366-9.
- 102 Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, Dekernion JB, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. *J Urol*. 1998;159(3):941-5.
- 103 Baretton GB, Klenk U, Diebold J, Schmeller N, Lohrs U. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. *Br J Cancer*. 1999;80(3-4):546-55.
- 104 Agnantis NJ, Constantinidou AE, Papaevagelou M, Apostolikas N. Comparative immunohistochemical study of ras-p21 oncoprotein in adenomatous hyperplasia and adenocarcinoma of the prostate gland. *Anticancer Res*. 1994;14(5B):2135-40.
- 105 Zincke H, Bergstralh EJ, Larson-Keller JJ, Farrow GM, Myers RP, Lieber MM, et al. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors. *Cancer*. 1992;70(1 Suppl):311-23.
- 106 Forsslund G, Esposti PL, Nilsson B, Zetterberg A. The prognostic significance of nuclear DNA content in prostatic carcinoma. *Cancer*. 1992;69(6):1432-9.
- 107 Blute ML, Nativ O, Zincke H, Farrow GM, Therneau T, Lieber MM. Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. *J Urol*. 1989;142(5):1262-5.
- 108 Forsslund G, Zetterberg A. Ploidy level determinations in high-grade and low-grade malignant variants of prostatic carcinoma. *Cancer Res*. 1990;50(14):4281-5.
- 109 Stephenson RA, James BC, Gay H, Fair WR, Whitmore WF, Jr., Melamed MR. Flow cytometry of prostate cancer: relationship of DNA content to survival. *Cancer Res*. 1987;47(9):2504-7.

- 110 Seay TM, Blute ML, Zincke H. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. *J Urol*. 1998;159(2):357-64.
- 111 Lee SE, Currin SM, Paulson DF, Walther PJ. Flow cytometric determination of ploidy in prostatic adenocarcinoma: a comparison with seminal vesicle involvement and histopathological grading as a predictor of clinical recurrence. *J Urol*. 1988;140(4):769-74.
- 112 Frankfurt OS, Chin JL, Englander LS, Greco WR, Pontes JE, Rustum YM. Relationship between DNA ploidy, glandular differentiation, and tumor spread in human prostate cancer. *Cancer Res*. 1985;45(3):1418-23.
- 113 Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. *J Urol*. 1996;156(3):1064-8.
- 114 Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, et al. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. *J Pathol*. 1996;178(4):437-41.
- 115 Aaltomaa S, Lipponen P, Vesalainen S, la-Opas M, Eskelinen M, Syrjanen K. Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. *Eur Urol*. 1997;32(4):410-5.
- 116 Astrom L, Weimarck A, Aldenborg F, Delle U, Hanson C, Verbiene I, et al. S-phase fraction related to prognosis in localised prostate cancer. No specific significance of chromosome 7 gain or deletion of 7q31.1. *Int J Cancer*. 1998;79(6):553-9.
- 117 Bratt O, Anderson H, Bak-Jensen E, Baldetorp B, Lundgren R. Metaphase cytogenetics and DNA flow cytometry with analysis of S-phase fraction in prostate cancer: influence on prognosis. *Urology*. 1996;47(2):218-24.
- 118 van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. *Nature*. 2002;415(6871):530-6.
- 119 van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. *N Engl J Med*. 2002;347(25):1999-2009.
- 120 Klotz L. Active surveillance for prostate cancer: For whom? *J Clin Oncol*. 2005;23(32):8165-9.
- 121 Bill-Axelsson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. *N Engl J Med*. 2005;352(19):1977-84.
- 122 Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlen BJ, et al. Quality of life after radical prostatectomy or watchful waiting. *N Engl J Med*. 2002;347(11):790-6.
- 123 Martin RM, Gunnell D, Hamdy F, Neal D, Lane A, Donovan J. Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. *J Urol*. 2006;176(2):439-49.
- 124 National Institute for Health and Clinical Excellence (NICE). Clinical Guideline. Prostate Cancer: diagnosis and treatment. Full Guideline. Draft for consultation. 2007 Jul.
- 125 National Institute for Health and Clinical Excellence (NICE). Clinical Guideline. Prostate Cancer: diagnosis and treatment. Evidence review. Draft for consultation. 2007 Jul.
- 126 Nilsson S, Norlen BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. *Acta Oncol*. 2004;43(4):316-81.
- 127 Medical Services Advisory Committee and Minister for Health and Ageing (MSAC). Brachytherapy for the treatment of prostate cancer. MSAC application 1089. Assessment report. 2005.
- 128 Norderhaug I, Dahl O, Hoisaeter PA, Heikkila R, Klepp O, Olsen DR, et al. Brachytherapy for prostate cancer: a systematic review of clinical and cost effectiveness. *Eur Urol*. 2003;44(1):40-6.

- 129 Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. *J Natl Cancer Inst.* 2004;96(18):1358-67.
- 130 Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. *Int J Radiat Oncol Biol Phys.* 2002;54(4):1063-8.
- 131 Morris DE, Emami B, Mauch PM, Konski AA, Tao ML, Ng AK, et al. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. *Int J Radiat Oncol Biol Phys.* 2005;62(1):3-19.
- 132 Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomized trial. *Lancet.* 1999;353(9149):267-72.
- 133 Koper PC, Stroom JC, van Putten WL, Korevaar GA, Heijmen BJ, Wijnmaalen A, et al. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. *Int J Radiat Oncol Biol Phys.* 1999;43(4):727-34.
- 134 Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. *Int J Radiat Oncol Biol Phys.* 2000;48(3):635-42.
- 135 Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. *Lancet Oncol.* 2007;8(6):475-87.
- 136 Maceira Rozas, García Caeiro, Rey Liste, Castro Bernárdez. Radioterapia de intensidad modulada. Santiago de Compostela: Servicio Galego de Saúde. Axencia de Avaliación de Tecnoloxías Sanitarias de Galicia, avalia-t; 2005. Serie Avaliación de Tecnoloxías. Investigación avaliativa; IA2005/01.
- 137 Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. *J Clin Oncol.* 2006;24(13):1990-6.
- 138 Peeters ST, Lebesque JV, Heemsbergen WD, van Putten WL, Slot A, Dielwart MF, et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys.* 2006;64(4):1151-61.
- 139 Hummel S, Paisley S, Morgan A, Currie E, Brewer N. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review. *Health Technol Assess.* 2003;7(33):iii, ix-iii,157.
- 140 National Institute for Health and Clinical Excellence (NICE). Interventional procedure overview of high intensity focused ultrasound (HIFU) for prostate cancer.
- 141 Shelley M, Wilt T, Coles B, Mason M. Cryotherapy for localised prostate cancer. *Cochrane Database Syst Rev.* 2007;(3):CD005010.
- 142 Llanos Méndez A, Villegas Portero R. Cirugía robótica mediante el sistema de telemanipulación robótica da Vinci® en la prostatectomía. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía; Madrid: Ministerio de Sanidad y Consumo de España, 2007.
- 143 National Institute for Health and Clinical Excellence (NICE). Interventional procedure overview of laparoscopic radical prostatectomy. 2006.
- 144 Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized Prostate cancer: 2007 update. *J Urol.* 2007; 177(6):2106-31
- 145 Blute ML. Radical prostatectomy by open or laparoscopic/robotic techniques: an issue of surgical device or surgical expertise? *J Clin Oncol.* 2008;26(14):2248-9.
- 146 Hu JC, Wang Q, Pashos CL, Lipsitz SR, Keating NL. Utilization and outcomes of minimally invasive radical prostatectomy. *J Clin Oncol.* 2008;26(14):2278-84.

- 147 Guazzoni G, Cestari A, Naspro R, Riva M, Centemero A, Zanoni M, et al. Intra- and peri-operative outcomes comparing radical retropubic and laparoscopic radical prostatectomy: results from a prospective, randomised, single-surgeon study. *Eur Urol.* 2006;50(1):98-104.
- 148 Sofer M, Hamilton-Nelson KL, Schlesselman JJ, Soloway MS. Risk of positive margins and biochemical recurrence in relation to nerve-sparing radical prostatectomy. *J Clin Oncol.* 2002;20(7):1853-8.
- 149 Tooher R, Swindle P, Woo H, Miller J, Maddern G. Laparoscopic radical prostatectomy for localized prostate cancer: a systematic review of comparative studies. *J Urol.* 2006;175(6):2011-7.
- 150 Allaf ME, Palapattu GS, Trock BJ, Carter HB, Walsh PC. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. *J Urol.* 2004;172(5 Pt 1):1840-4.
- 151 Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? *J Urol.* 2003;169(3):849-54.
- 152 Clark T, Parekh DJ, Cookson MS, Chang SS, Smith ER, Jr., Wells N, et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. *J Urol.* 2003;169(1):145-7.
- 153 Bhatta-Dhar N, Reuther AM, Zippe C, Klein EA. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. *Urology.* 2004;63(3):528-31.
- 154 Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. *J Urol.* 2004;172(6 Pt 1):2227-31.
- 155 Wille S, Heidenreich A, Hofmann R, Engelmann U. Preoperative erectile function is one predictor for post prostatectomy incontinence. *Neurourol Urodyn.* 2007;26(1):140-3.
- 156 Jerezek-Fossa BA, Orecchia R. Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. *Radiother Oncol.* 2007;84(2):197-215.
- 157 Khuntia D, Reddy CA, Mahadevan A, Klein EA, Kupelian PA. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect? *Cancer.* 2004;100(6):1283-92.
- 158 Kupelian PA, Buchsbaum JC, Reddy CA, Klein EA. Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason  $\leq$  6, and pretreatment prostate-specific antigen  $\leq$  10). *Int J Radiat Oncol Biol Phys.* 2001;50(3):621-5.
- 159 Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. *J Clin Oncol.* 2000;18(23):3904-11.
- 160 Hanks GE, Hanlon AL, Epstein B, Horwitz EM. Dose response in prostate cancer with 8-12 years' follow-up. *Int J Radiat Oncol Biol Phys.* 2002;54(2):427-35.
- 161 Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. *Int J Radiat Oncol Biol Phys.* 2005;61(3):695-701.
- 162 Roach M, III, DeSilvio M, Valicenti R, Grignon D, Asbell SO, Lawton C, et al. Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. *Int J Radiat Oncol Biol Phys.* 2006;66(3):647-53.
- 163 Roach M, III, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. *J Clin Oncol.* 2003;21(10):1904-11.

- 164 Vargas CE, Galalae R, Demanes J, Harsolia A, Meldolesi E, Nurnberg N, et al. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation. *Int J Radiat Oncol Biol Phys.* 2005;63(5):1474-82.
- 165 Borque Fernando A, Sanz G, Esteban LM, Gil Sanz MJ, Gil Martínez P, García de Jalón A, et al. Vigencia actual de los nomogramas en la estadificación del cáncer de próstata. *Arch Esp Urol.* 2006;59(10):989-1000.
- 166 Lawton CA, DeSilvio M, Roach M, III, Uhl V, Kirsch R, Seider M, et al. An Update of the Phase III Trial Comparing Whole Pelvic to Prostate Only Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression: Updated Analysis of RTOG 94-13, with Emphasis on Unexpected Hormone/Radiation Interactions. *Int J Radiat Oncol Biol Phys.* 2007;69(3):646-55.
- 167 Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. *J Clin Oncol.* 2005;23(25):6132-8.
- 168 Yeoh EE, Holloway RH, Fraser RJ, Botten RJ, Di Matteo AC, Butters J, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. *Int J Radiat Oncol Biol Phys.* 2006;66(4):1072-83.
- 169 Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. *Int J Radiat Oncol Biol Phys.* 2007;68(5):1424-30.
- 170 Higgins GS, McLaren DB, Kerr GR, Elliott T, Howard GC. Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy. *Int J Radiat Oncol Biol Phys.* 2006;65(4):982-9.
- 171 Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. *Cochrane Database Syst Rev.* 2006;(4):CD006019.
- 172 McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP. Bicalutamide 150 mg plus standard care vs standar care alone for early prostate cancer. *BJU Int.* 2005;97(2):247-54.
- 173 D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. *JAMA.* 2004;292(7):821-7.
- 174 Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. *Urol Clin North Am.* 2001;28(3):555-65.
- 175 Kupelian PA, Mahadevan A, Reddy CA, Reuther AM, Klein EA. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. *Urology.* 2006;68(3):593-8.
- 176 American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. *Int J Radiat Oncol Biol Phys.* 1997;37(5):1035-41.
- 177 Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. *Lancet Oncol.* 2005;6(11):841-50.
- 178 Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. *Int J Radiat Oncol Biol Phys.* 2001;50(5):1243-52.
- 179 Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced

- ced prostate cancer (an EORTC study): a phase III randomised trial. *Lancet*. 2002;360(9327):103-6.
- 180 Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. *Int J Radiat Oncol Biol Phys*. 2005;61(5):1285-90.
- 181 Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. *Radiother Oncol*. 2005;76(1):4-10.
- 182 Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. *JAMA*. 2005;294(2):238-44.
- 183 Akakura K, Suzuki H, Ichikawa T, Fujimoto H, Maeda O, Usami M, et al. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. *Jpn J Clin Oncol*. 2006;36(12):789-93.
- 184 Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. *BJU Int*. 2004;93(7):975-9.
- 185 Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ, Jr., Lilja H, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. *J Clin Oncol*. 2006;24(24):3973-8.
- 186 National Institute for Health and Clinical Excellence (NICE). Intervencional procedures overview of cryotherapy as a primary treatment for prostate cancer. 2005.
- 187 Bolla M, Van PH, Collette L, van CP, Vekemans K, Da PL, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). *Lancet*. 2005;366(9485):572-8.
- 188 Bolla M, Van PH, Collette L. Résultats préliminaires de l'essai EORTC 22911 : prostatectomie radicale suivie ou non de radiothérapie postopératoire dans les cancers de la prostate à haut risque de récurrence. *Cancer Radiother*. 2007;11(6-7):363-9.
- 189 Lennernas B, Edgren M, Haggman M, Norlen BJ, Nilsson S. Postoperative radiotherapy after prostatectomy--a review. *Scand J Urol Nephrol*. 2003;37(1):10-5.
- 190 MacDonald OK, Schild SE, Vora S, Andrews PE, Ferrigni RG, Novicki DE, et al. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ? *Urology*. 2004;64(4):760-4.
- 191 El-Galley RES, Keane TE, Petros JA, Sanders WH, Clarke HS, Cotsonis GA, et al. Evaluation of staging lymphadenectomy in prostate cancer. *Urology*. 1998;52(4):663-7.
- 192 Han M, Pound CR, Potter SR, Partin AW, Epstein JI, Walsh PC. Isolated local recurrence is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins: therapeutic implications. *J Urol*. 2001;165(3):864-6.
- 193 Rosser CJ, Chichakli R, Levy LB, Kuban DA, Smith LG, Pisters LL. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation. *J Urol*. 2002;168(2):536-41.
- 194 Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. *J Urol*. 2005;173(3):797-802.
- 195 Taylor JA, III, Koff SG, Dauser DA, McLeod DG. The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy. *BJU Int*. 2006;98(3):540-3.

- 196 Roach M, III, Hanks G, Thames H, Jr., Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. *Int J Radiat Oncol Biol Phys.* 2006;65(4):965-74.
- 197 Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. *Int J Radiat Oncol Biol Phys.* 2006;65(5):1487-93.
- 198 Kuban D, Thames H, Levy L, Horwitz E, Kupelian P, Martinez A, et al. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all? *Int J Radiat Oncol Biol Phys.* 2005;61(2):409-14.
- 199 Quero L, Mongiat-Artus P, Ravery V, Maylin C, Desgrandchamps F, Hennequin C. Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: a single institution experience. *BMC Cancer.* 2008;8(1):26.
- 200 Pazona JF, Han M, Hawkins SA, Roehl KA, Catalona WJ. Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates. *J Urol.* 2005;174(4 Pt 1):1282-6.
- 201 Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. *JAMA.* 2004;291(11):1325-32.
- 202 Brooks JP, Albert PS, Wilder RB, Gant DA, McLeod DG, Poggi MM. Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors. *J Urol.* 2005;174(6):2204-8, discussion.
- 203 Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. *JAMA.* 2005;294(4):433-9.
- 204 D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. *J Urol.* 2004;172(5 Pt 2):S42-S46.
- 205 Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. *J Urol.* 2004;171(3):1141-7.
- 206 Ward JF, Sebo TJ, Blute ML, Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. *J Urol.* 2005;173(4):1156-60.
- 207 Grossfeld GD, Stier DM, Flanders SC, Henning JM, Schonfeld W, Warolin K, et al. Use of second treatment following definitive local therapy for prostate cancer: data from the caPSUR-RE database. *J Urol.* 1998;160(4):1398-404.
- 208 Faria SL, Mahmud S, Souhami L, David M, Duclos M, Shenouda G, et al. No immediate treatment after biochemical failure in patients with prostate cancer treated by external beam radiotherapy. *Urology.* 2006;67(1):142-6.
- 209 Pinover WH, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. *Cancer.* 2003;97(4):1127-33.
- 210 Bianco FJ, Jr., Scardino PT, Stephenson AJ, DiBlasio CJ, Fearn PA, Eastham JA. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. *Int J Radiat Oncol Biol Phys.* 2005;62(2):448-53.
- 211 Stephenson AJ, Scardino PT, Bianco FJ, Jr., DiBlasio CJ, Fearn PA, Eastham JA. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. *J Urol.* 2004;172(6 Pt 1):2239-43.
- 212 Grado GL, Collins JM, Kriegshauser JS, Balch CS, Grado MM, Swanson GP, et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. *Urology.* 1999;53(1):2-10.

- 213 Pisters LL, Leibovich BC, Izawa J, Blute ML, Madsen L, Scott S, et al. A comparison of biochemical outcome following salvage prostatectomy or cryosurgery for locally recurrent prostate cancer after radiation therapy. *International journal of radiation oncology, biology, physics*. 2006;51:294.
- 214 Pisters LL, von Eschenbach AC, Scott SM, Swanson DA, Dinney CP, Pettaway CA, et al. The efficacy and complications of salvage cryotherapy of the prostate. *J Urol*. 1997;157(3):921-5.
- 215 Cespedes RD, Pisters LL, von Eschenbach AC, McGuire EJ. Long-term followup of incontinence and obstruction after salvage cryosurgical ablation of the prostate: results in 143 patients. *J Urol*. 1997;157(1):237-40.
- 216 Gelet A, Chapelon JY, Poissonnier L, Bouvier R, Rouviere O, Curiel L, et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. *Urology*. 2004;63(4):625-9.
- 217 Nair B, Wilt T, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. *Cochrane Database Syst Rev*. 2002;(1):CD003506.
- 218 Conti P, Atallah A, Arruda H, Soares B, El DR, Wilt T. Intermittent versus continuous androgen suppression for prostatic cancer. *Cochrane Database Syst Rev*. 2007;(4):CD005009.
- 219 de Leval J, Boca P, Yousef E, Nicolas H, Jeukenne M, Seidel L, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. *Clin Prostate Cancer*. 2002;1(3):163-71.
- 220 Calais F, Bono A, Wkealan P. Phase III study of intermittent MAB versus continuous MAB international cooperative study. *Eur Urol*. 2002;419(Suppl):A 531.
- 221 García JR, Simó M, Pérez G, Soler M, López S, Setoain X, et al. Diagnóstico y valoración de la respuesta terapéutica de las metástasis óseas mediante gammagrafía ósea y estudio PET. *Rev Esp Med Nucl*. 2004;23(3):197-201.
- 222 Schmitt B, Wilt TJ, Schellhammer PF, DeMasi V, Sartor O, Crawford ED, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. *Urology*. 2001;57(4):727-32.
- 223 Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, et al. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. *Evid Rep Technol Assess (Summ)*. 1999;(4):i-x<sub>1</sub>,1-246,11-36, passim.
- 224 Dalesio O, Van Tinteren H, Clarke M, Peto R, Schroder FH. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. *Prostate Cancer Trialists' Collaborative Group. Lancet*. 2000;355(9214):1491-8.
- 225 Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T. Maximal androgen blockade for advanced prostate cancer. *Cochrane Database Syst Rev*. 2000;(2);CD001526.
- 226 Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. *Cancer*. 2002;95(2):361-76.
- 227 Collette L, Studer UE, Schroder FH, Denis LJ, Sylvester RJ. Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences. *Prostate*. 2001;48(1):29-39.
- 228 Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. *BJU Int*. 2004;93(9):1177-82.
- 229 Moinpour CM, Savage MJ, Troxel A, Lovato LC, Eisenberger M, Veith RW, et al. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. *J Natl Cancer Inst*. 1998;90(20):1537-44.

- 230 Jordan WP, Jr., Blackard CE, Byar DP. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. *South Med J*. 1977;70(12):1411-3.
- 231 Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. *J Clin Oncol*. 2007;25(12):1596-605.
- 232 Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. *N Engl J Med*. 1999;341(24):1781-8.
- 233 Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. *Cancer*. 1973;32(5):1126-30.
- 234 Lane TM, Ansell W, Farrugia D, Wilson P, Williams G, Chinegwundoh F, et al. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. *Urol Int*. 2004;73(2):117-22.
- 235 Hering F, Rodrigues PRT, Lipay MA, Nesrallah L, Srougi M. Metastatic adenocarcinoma of the prostate: comparison between continuous and intermittent hormonal treatment. *Braz J Urol*. 2000;26:276-82.
- 236 Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group trial 9346 (INT-0162). *J Clin Oncol*. 2006;24(24):3984-90.
- 237 Shelley M, Harrison C, Coles B, Staffurth J, Wilt TJ, Mason MD. Chemotherapy for hormone-refractory prostate cancer. *Cochrane Database Syst Rev*. 2006;(4):CD005247.
- 238 Johansson JE, Andersson SO, Holmberg L. High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study. *Br J Urol*. 1991;68(1):67-73.
- 239 Dreicer R, Carducci M. E-1899: An Eastern Cooperative Oncology Group Study Comparing Ketoconazole Plus Hydrocortisone with Docetaxel Plus Estramustine for Asymptomatic, Androgen-Independent, Nonmetastatic Prostate Cancer Patients with Rising PSA Levels. *Rev Urol*. 2003;5 Suppl 2:S35-41.
- 240 Carducci MA. What is more exciting? The activity of docetaxel in early prostate cancer or the successful collaboration between urologists and medical oncologists to complete a study in early prostate cancer? *J Clin Oncol*. 2005;23(15):3304-7.
- 241 Ryan CJ, Eisenberger M. Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?". *J Clin Oncol*. 2005;23(32):8242-6.
- 242 Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). *J Clin Oncol*. 2004;22(6):1025-33.
- 243 Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. *N Engl J Med*. 2004;351(15):1513-20.
- 244 Tannock IF, de WR, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med*. 2004;351(15):1502-12.
- 245 Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. *J Clin Oncol*. 1999;17(8):2506-13.
- 246 Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. *J Urol*. 2002;168(6):2439-43.

- 247 Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. *J Clin Oncol.* 1996;14(6):1756-64.
- 248 Oudard S, Banu E, Beuzebec P, Voog E, Dourthe LM, Hardy-Bessard AC, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. *J Clin Oncol.* 2005;23(15):3343-51.
- 249 Eymard JC, Priou F, Zannetti A, Ravaud A, Lepille D, Kerbrat P, et al. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. *Ann Oncol.* 2007;18(6):1064-70.
- 250 Moreau JP, Delavault P, Blumberg J. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: A review of their discovery, development, and place in therapy. *Clin Ther.* 2006;28(10):1485-508.
- 251 Zerbib M. Contribution of LHRH analogs in prostate cancer treatment. *Ann Urol (Paris).* 2007;41 Suppl 3:S83-6.
- 252 Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD. Bisphosphonates for advanced prostate cancer. *Cochrane Database Syst Rev.* 2006;(4):CD006250.
- 253 Cózar Olmo JM, Carballido Rodríguez J, Luque Gálvez P, Tabernero Gómez AG, Barreiro Mouro A, Sánchez Sánchez E, et al. Efectividad y tolerabilidad del ácido zoledrónico en el tratamiento del cáncer de próstata metastásico. *Actas Urol Esp.* 2008;32(5):492-501.
- 254 Diamond TH, Winters J, Smith A, De SP, Kersley JH, Lynch WJ, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. *Cancer.* 2001;92(6):1444-50.
- 255 Nelson JB, Greenspan SL, Resnick NM, Trump DL, Parker RA. Once weekly oral alendronate prevents bone loss in men on androgen deprivation therapy for prostate cancer. *ASCO 2006 Prostate Cancer Symposium, Abstract 139.* 2006.
- 256 Magno C, Anastasi G, Morabito N, Gaudio A, Maisano D, Franchina F, et al. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate. *Eur Urol.* 2005;47(5):575-80.
- 257 Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. *N Engl J Med.* 2001;345(13):948-55.
- 258 Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. *J Urol.* 2003;169(6):2008-12.
- 259 Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. *J Natl Cancer Inst.* 2002;94(19):1458-68.
- 260 Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. *J Natl Cancer Inst.* 2004;96(11):879-82.
- 261 Saad F. Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma. *Eur Urol Suppl.* 2007;6(11):683-8.
- 262 Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. *Ann Oncol.* 2008;19(3):420-32.
- 263 Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. *Clin Ther.* 2007;29(8):1548-58.

- 264 Agencia Española de Medicamentos y Productos Sanitarios. Bifosfonatos de Administración Parenteral y Osteonecrosis del Maxilar. Nota informativa sobre Bifosfonatos. Ref: 2008/17. Última actualización: 8 de noviembre de 2005 [consultada 31 marzo de 2008]. Disponible en: <http://www.agemed.es/actividad/alertas/usoHumano/seguridad/bisfosfonatos.htm>
- 265 Roqué M, Martínez MJ, Alonso P, Catalá E, García JL, Ferrandiz M. Radioisotopes for metastatic bone pain. *Cochrane Database Syst Rev.* 2003;(4):CD003347.
- 266 Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. *Eur J Cancer.* 1991;27(8):954-8.
- 267 Buchali K, Correns HJ, Schuerer M, Schnorr D, Lips H, Sydow K. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. *Eur J Nucl Med.* 1988;14(7-8):349-51.
- 268 Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. *Int J Radiat Oncol Biol Phys.* 1993;25(5):805-13.
- 269 Smeland S, Erikstein B, Aas M, Skovlund E, Hess SL, Fossa SD. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. *Int J Radiat Oncol Biol Phys.* 2003;56(5):1397-404.
- 270 Oosterhof GO, Roberts JT, de Reijke TM, Engelholm SA, Horenblas S, von der Maase H, et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. *Eur Urol.* 2003;44(5):519-26.
- 271 Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. *Radiother Oncol.* 1994;31(1):33-40.
- 272 Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. *Urology.* 2004;63(5):940-5.
- 273 Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. *Lancet.* 2001;357(9253):336-41.
- 274 Carretier J, Coloby P, Pommier P, Richaud P, Ruffion A, Villers A. Comprendre le cancer de la prostate. Guide d'information et de dialogue à l'usage des personnes malades et de leurs proches, 2005 © FNCLCC [consultada 31 de marzo de 2008]. Disponible en: <http://www.sor-cancer.fr>.
- 275 Kuban DA, Thames HD, Shipley WU. Defining recurrence after radiation for prostate cancer. *J Urol.* 2005;173(6):1871-8.
- 276 Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. *J Urol.* 2002;167(4):1664-9.
- 277 Lujan Galán M, García Tello A, Pascual Mateo C, Llanes González L, García Mediero JM, Ángulo Cuesta J, et al. Prevalencia y significado clínico de los cánceres de próstata focales e incidentales. *Actas Urol Esp.* 2007;31(8):819-24.